Yuasa Akira, Murata Tatsunori, Imai Keiji, Yamamoto Yuji, Fujimoto Yoko
Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan.
SAGE Open Med. 2019 Aug 24;7:2050312119871181. doi: 10.1177/2050312119871181. eCollection 2019.
This study aimed to determine the patient characteristics, treatment procedures, and medical costs of methicillin-resistant infections in clinical practice in Japan.
Using the MinaCare database of healthcare information covering nearly 3 million individuals, of which 90% were aged 20-59 years, we extracted and analyzed data of patients who were aged ⩾15 years and diagnosed with methicillin-resistant during hospitalization between April 2010 and August 2015.
A total of 684 patients with methicillin-resistant infection were listed in the database, of which 365 were eligible to be included in this study. Mean patient age was 52.9 years, and 31.5% of the patients were females. Methicillin-resistant bacteremia was the most common methicillin-resistant infection (32.9%) with a mean age of 48.5 years, followed by pneumonia (24.1%) with a mean age of 61.0 years and methicillin-resistant surgical site infection (6.3%) with a mean age of 49.7 years. Vancomycin was the most frequently prescribed anti-methicillin-resistant drug used as the first-line therapy (68.5%), followed by teicoplanin (14.2%), linezolid (7.9%), arbekacin (5.8%), and daptomycin (3.6%). The mortality rate was 11.0%, and the mean treatment duration was 13.3 days. The median total medical cost per patient was US$5083. The median treatment cost for methicillin-resistant bacteremia was the highest among the methicillin-resistant infections at US$9099, followed by methicillin-resistant pneumonia at US$3676 and surgery site infections at US$2084.
Although the proportion of patients with methicillin-resistant is very small in the employment-based health insurance database, methicillin-resistant bacteremia is the most common methicillin-resistant infection in the working-age population and requires the highest medical cost. Methicillin-resistant pneumonia is more common in the elderly and is a cause of high mortality.
本研究旨在确定日本临床实践中耐甲氧西林感染的患者特征、治疗程序和医疗费用。
利用涵盖近300万人的医疗保健信息MinaCare数据库(其中90%年龄在20 - 59岁之间),我们提取并分析了2010年4月至2015年8月期间年龄≥15岁且在住院期间被诊断为耐甲氧西林感染的患者数据。
数据库中共有684例耐甲氧西林感染患者,其中365例符合纳入本研究的条件。患者平均年龄为52.9岁,31.5%为女性。耐甲氧西林菌血症是最常见的耐甲氧西林感染(32.9%),平均年龄为48.5岁,其次是肺炎(24.1%),平均年龄为61.0岁,耐甲氧西林手术部位感染(6.3%),平均年龄为49.7岁。万古霉素是最常作为一线治疗使用的抗耐甲氧西林药物(68.5%),其次是替考拉宁(14.2%)、利奈唑胺(7.9%)、阿贝卡星(5.8%)和达托霉素(3.6%)。死亡率为11.0%,平均治疗持续时间为13.3天。每位患者的医疗费用中位数为5083美元。耐甲氧西林菌血症的治疗费用中位数在耐甲氧西林感染中最高,为9099美元,其次是耐甲氧西林肺炎,为3676美元,手术部位感染为2084美元。
尽管在基于就业的健康保险数据库中耐甲氧西林感染患者的比例非常小,但耐甲氧西林菌血症是劳动年龄人群中最常见的耐甲氧西林感染,且医疗费用最高。耐甲氧西林肺炎在老年人中更为常见,是高死亡率的一个原因。